India-based precision oncology company OneCell Diagnostics announced on Tuesday the launch of OncoIncytes, a comprehensive multi-modal cancer diagnostic panel that integrates multiple types of data including Circulating Tumour DNA (ctDNA), Circulating Tumour Cells (CTCs) at single cell resolution, RNA transcriptomics and Proteomics (150 proteins at the single cell level).

The company is also rebranding as 1Cell.Ai, focused on combining its science expertise with advanced data science capabilities.

OncoIncytes' technology employs a 1080 gene panel and leverages artificial intelligence and machine learning models designed to deliver deeper insights into clinical decision-making. Its primary innovation enables pharmaceutical and biotech companies to advance antibody-drug conjugates (ADCs) development during early-stage clinical studies by detecting protein expression on cell surfaces that other liquid biopsy tests cannot identify. Healthcare providers can now request sample collection kits to be shipped to the 1Cell.Ai lab from hospitals and clinical trial sites. Once samples are collected, the team processes the data and uploads results through the iDiscover application. 1Cell.Ai's laboratory at Foster City has recently been CLIA-certified.

"By integrating true single cell level multi-omics data with ctDNA, OncoIncytes provides unparalleled information to oncologists that enhances critical clinical decisions," said Mohan Uttarwar, 1Cell.Ai CEO and co-founder. "This approach offers unprecedented sensitivity and specificity to optimise clinical trial successes, particularly in early-stage research. For antibody-drug conjugate studies, this represents a unique way to select the most appropriate patients, and address one of the most significant challenges in translational research."